Regardless of which pathways of Gal-1 and Gal-3 play a role in HSCs, results from the current study demonstrate that targeting either Gal-1 or Gal-3 can lead to effective results in suppressing HSC activation and liver fibrosis. This evidence concerns the gene LGALS3 and Hepatic fibrosis.